Brief: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)
25/06/2025 13:24
June 25 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL HIGHLIGHTS POSITIVE TOPLINE RESULTS FROM CONFIRMATORY CLINICAL STUDY OF BIOSIMILAR CANDIDATE TO XOLAIR(R) (OMALIZUMAB), DEVELOPED BY KASHIV BIOSCIENCES AMNEAL PHARMACEUTICALS INC - ADL-018 CLINICAL STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS AMNEAL PHARMACEUTICALS INC - BLA FOR ADL-018 EXPECTED TO BE SUBMITTED TO FDA IN Q4 2025 Source text: ID:nGNXktkYK Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study